Evidence map›Paper›PMID 40484290›Full record

ReviewThe Journal of allergy and clinical immunology2025

Informed clinical decisions by outfoxing human FOXN1 variants.

Christian A Wysocki, Nicolai S C van Oers

Abstract readReview
In one paragraph

Review in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christian A WysockiDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Tex; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Tex. Electronic address: christian.wysocki@utsouthwestern.edu.
Nicolai S C van OersDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Tex; Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Tex; Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Tex. Electronic address: Nicolai.vanoers@utsouthwestern.edu.

Funding

Long noncoding RNAs and their contribution to 22q11.2 deletion syndromeR01AI114523 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI VAN OERS, NICOLAI STANISLAS CYRILLE · 2015 to 2024
$4.1M
T CELL RECEPTOR SIGNALING BY PHOSPHORYLATED FORMS OF TCRR01AI042953 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI VAN OERS, NICOLAI STANISLAS CYRILLE · 1999 to 2008
$2.4M
FOXN1 variant regulation of T cell productionR21AI188004 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI VAN OERS, NICOLAI STANISLAS CYRILLE · 2025 to 2025
$436k
NIAID NIH HHS R01 AI042953NIAID NIH HHS R01 AI114523NIAID NIH HHS R21 AI188004
6 · The paper itself

Abstract

Thymic T-cell development is orchestrated by thymic epithelial cells. The master transcriptional regulator of these cells is forkhead box N1 (FOXN1), which controls their differentiation, expansion, and function. Biallelic founder mutations in FOXN1 caused a nude/severe combined immunodeficiency phenotype due to congenital thymic aplasia and alopecia universalis. This established the critical role of FOXN1 in thymic epithelial cells and epithelial cells in the skin and nails. The emergence of newborn screening for severe T-cell deficiency via the T-cell receptor excision circle assay, along with exome and genome sequencing, has led to dramatic increases in the number of FOXN1 variants identified. The consequent impact of the FOXN1 variants ranges from pathogenic to benign, yet most FOXN1 mutations are listed as variants of unknown significance. Among monoallelic FOXN1 variants are some that act as dominant negative, resulting in a transient T-cell lymphopenia. In this review, the clinical impacts of diverse FOXN1 variants are categorized by mutation type and location. Knowing how these FOXN1 mutations affect protein function informs clinical care as well as laboratory monitoring, prophylactic measures, and allogeneic thymic implant decisions. This review provides key functional insights into FOXN1, enabling better clinical care.

Indexed as

Forkhead Transcription FactorsSevere Combined ImmunodeficiencyT-LymphocytesAnimalsClinical Decision-MakingHumansMutationThymus GlandForkhead Transcription FactorsWhn proteinCIDFOXN1, thymic epithelial cellsSCIDT-cell immunodeficiencyTECsthymic implantsthymopoiesisTRECs

Identifiers

PMID40484290
PMCPMC13430552

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.